Characteristics of the SS-RBCs Used in Rats Treated With Systemic L/D-NAME
| Group . | Reticulocytes (%) . | MCV (fL) . | MCH (pg) . | MCHC . |
|---|---|---|---|---|
| . | . | . | . | (g/dL) . |
| LN-SS stroke | 8.8 (3.0) | 86 (16) | 29.3 (6.2) | 33.9 (1.4) |
| LN-SS alive | 8.5 (4.8) | 83 (11) | 28.1 (3.8) | 34.0 (0.8) |
| DN-SS | 9.5 (6.9) | 86 (4) | 29.5 (1.9) | 34.3 (0.9) |
| Group . | Reticulocytes (%) . | MCV (fL) . | MCH (pg) . | MCHC . |
|---|---|---|---|---|
| . | . | . | . | (g/dL) . |
| LN-SS stroke | 8.8 (3.0) | 86 (16) | 29.3 (6.2) | 33.9 (1.4) |
| LN-SS alive | 8.5 (4.8) | 83 (11) | 28.1 (3.8) | 34.0 (0.8) |
| DN-SS | 9.5 (6.9) | 86 (4) | 29.5 (1.9) | 34.3 (0.9) |
Shown is the mean (± SD) reticulocyte count, MCV, MCH, and MCHC of the SS-RBCs that were infused into rats systemically treated with L/D-NAME. LN-SS stroke is the group of rats treated with L-NAME and SS-RBCs that developed stroke. LN-SS alive is the group of rats treated with L-NAME and SS-RBCs that survived. DN-SS is the group of rats treated with D-NAME and SS-RBCs. There was no significant difference in the reticulocyte count, MCV, MCH, or MCHC between any of these groups (P > .05, Student's t-test). SS-RBCs were from different donors for every experiment. To obtain the necessary volume of RBCs, in four experiments more than one patient's SS-RBCs were sequentially infused into a single rat (2 experiments in the LN-SS stroke group, 1 experiment in the LN-SS alive group, and 1 experiment in the DN-SS group).